Skip to content
value.today

Lineage Cell Therapeutics, Inc.

LCTX
$261 Mmarket cap on Oct 30, 2026+22.3% since Jan 2024
Compare
World rank
#15,316
Revenue
$15 M
For year ending December-2025
Net income
$-64 M
-436.3% margin
SEC filing
Employees
—

Lineage Cell Therapeutics, Inc. in brief

Lineage Cell Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Carlsbad, California, USA. It was founded in 1990. Its market value was $261 M on 30 October 2026, which makes it the 15,316th largest listed company in the world and the 2,986th largest in the USA on this site. In the year to December 2025 it had sales of $15 M and a net loss of $64 M. Brian M. Culley is its chief executive. Its largest product and service lines by sales in 2025 were Collaboration Revenues (93%), Event Based Milestones and Other Collaborative Revenue (49%) and Upfront license fees (44%). Its shares trade under the symbol LCTX (NYSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a Clinical Stage Biotechnology company developing novel cellular therapies to treat unmet medical needs. The company total assets are 107.9 million USD as on 2020. The headquarters is in USA.

Lineage Cell Therapeutics, Inc. timeline

4 events, 1990–2022
  1. 1990
  2. 🏁
    Founded
  3. 1996
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2019
  6. ✎
    Renamed Lineage Cell Therapeutics, Inc.
    Formerly Biotime Inc.
  7. 2022
  8. 💰
    Record revenue of $15 million
    FY2022, the highest of the 8 years on record.

Events of Lineage Cell Therapeutics, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$115 M$230 M$345 M$460 M2023202420252026

World rank over time

▲ up 1,291 places since 2022
2022-01-07: #16648#16,64820222022-12-25: #19121#19,12120222023-07-30: #17949#17,94920232024-01-05: #17560#17,56020242026-03-08: #7487#7,48720262026-08-01: #14532#14,53220262026-10-14: #15827#15,82720262026-10-30: #15357#15,3572026

Rank in USA: #3,476 (Jan 2022) · #3,869 (Dec 2022) · #3,587 (Jul 2023) · #3,201 (Jan 2024) · #1,323 (Mar 2026) · #2,933 (Aug 2026) · #3,051 (Oct 2026) · #2,990 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
148.9×
Price / sales (TTM)
24.0×
Price / book
5.8×
Free cash flow yield
-7.5%
Net margin (TTM)
16.1%
Operating margin
-251.5%
Return on equity
3.9%
Liabilities / assets
61.5%
Revenue growth
+53.3%
R&D / revenue
121.8%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $5M, net income $-46M$5MFY18Fiscal year ending Dec 2019: revenue $4M, net income $-12M$4MFY19Fiscal year ending Dec 2020: revenue $2M, net income $-21M$2MFY20Fiscal year ending Dec 2021: revenue $4M, net income $-43M$4MFY21Fiscal year ending Dec 2022: revenue $15M, net income $-26M$15MFY22Fiscal year ending Dec 2023: revenue $9M, net income $-21M$9MFY23Fiscal year ending Dec 2024: revenue $10M, net income $-19M$10MFY24Fiscal year ending Dec 2025: revenue $15M, net income $-64M$15MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$15M+53.3%$-37M$-64M-436.3%
Dec 2024$10M+6.3%$-21M$-19M-195.9%
Dec 2023$9M-39.2%$-25M$-21M-240.4%
Dec 2022$15M+238.7%$-23M$-26M-178.7%
Dec 2021$4M+137.2%$-49M$-43M-991.2%
Dec 2020$2M-48.0%$-26M$-21M-1128.4%
Dec 2019$4M-29.5%$-39M$-12M-332.7%
Dec 2018$5M—$-42M$-46M-921.6%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-19M$1M$-19M$-0.28—
Dec 2024$-23M$1M$-24M$-0.09—
Dec 2023$-29M$1M$-29M$-0.12—
Dec 2022$1M$0M$1M$-0.15—
Dec 2021$-24M$0M$-24M$-0.26—
Dec 2020$-20M$0M$-20M$-0.14—
Dec 2019$-32M$0M$-32M$-0.08—
Dec 2018$-31M$1M$-31M$-0.36—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$11M
Net income, trailing 12 months
$2M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $3M, net income $-3M$3MDec ’24Three months to Mar 2025: revenue $2M, net income $-4M$2MMar ’25Three months to Jun 2025: revenue $3M, net income $-30M$3MJun ’25Three months to Sep 2025: revenue $4M, net income $-30M$4MSep ’25Three months to Dec 2025 (from the annual report): revenue $7M, net income $1M$7MDec ’25Three months to Mar 2026: revenue $2M, net income $-5M$2MMar ’26Three months to Jun 2026: revenue $1M, net income $1M$1MJun ’26Three months to Sep 2026: revenue $1M, net income $4M$1MSep ’26

Latest quarter to Sep 2026: revenue $1M (-61.1% on a year earlier), net income $4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Lineage Cell Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$15 M
Operating income
$-37 M
Net income
$-64 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$113 M
Total liabilities
$69 M
Total equity
$45 M

As of December-2025

Top 100 institutional investors in Lineage Cell Therapeutics, Inc.#

As of Sep 30, 2026
143 institutions held 117.2 M shares (about 46.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 40.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Lineage Cell Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Broadwood Capital Inc49,560,9920 (0.00%)19.59%$47 MNov 16, 2026
2BlackRock, Inc.13,870,871+683,976 (+5.19%)5.48%$13 MNov 13, 2026
3Vanguard Capital Management LLC8,775,663-279,255 (-3.08%)3.47%$8 MNov 13, 2026
4Defender Capital, LLC.6,648,899+50,000 (+0.76%)2.63%$6 MOct 1, 2026
5Geode Capital Management, LLC5,339,354+39,897 (+0.75%)2.11%$5 MNov 6, 2026
6Raffles Associates LP5,197,7880 (0.00%)2.05%$5 MNov 16, 2026
7Fifth Third Bancorp4,900,000+300,000 (+6.52%)1.94%$5 MNov 5, 2026
8State Street Corp2,925,731+611,551 (+26.43%)1.16%$3 MNov 12, 2026
9Millennium Management LLC2,628,150-390,417 (-12.93%)1.04%$3 MNov 16, 2026
10Vanguard Fiduciary Trust Co1,715,125+46,496 (+2.79%)0.68%$2 MNov 13, 2026
11Northern Trust Corp1,657,655+1,004 (+0.06%)0.66%$2 MNov 16, 2026
12Vanguard Portfolio Management LLC1,299,569+26,258 (+2.06%)0.51%$1 MNov 13, 2026
13UBS Group AG1,160,527+473,476 (+68.91%)0.46%$1 MNov 10, 2026
14Morgan Stanley810,539-660,923 (-44.92%)0.32%$1 MNov 13, 2026
15Renaissance Technologies LLC674,529-670,300 (-49.84%)0.27%$1 MNov 12, 2026
16Charles Schwab Investment Management Inc577,993+558 (+0.10%)0.23%$1 MNov 16, 2026
17Goldman Sachs Group Inc537,965+104,699 (+24.17%)0.21%$1 MNov 16, 2026
18Red Crane Wealth Management, LLC506,460-90,803 (-15.20%)0.20%$0 MOct 14, 2026
19Hofer & Associates. Inc506,460New0.20%$0 MOct 13, 2026
20Dauntless Investment Group, LLC422,500+422,400 (+422400.00%)0.17%$0 MNov 16, 2026
21Barclays PLC394,628-114,040 (-22.42%)0.16%$0 MNov 6, 2026
22Bank of New York Mellon Corp391,6750 (0.00%)0.15%$0 MNov 5, 2026
23Citadel Advisors LLC341,881-84,288 (-19.78%)0.14%$0 MNov 16, 2026
24Flputnam Investment Management Co308,613+4,051 (+1.33%)0.12%$0 MNov 13, 2026
25Quadrature Capital Ltd300,156+290,110 (+2887.82%)0.12%$0 MNov 13, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Lineage Cell Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Nuveen, LLC298,853+53,469 (+21.79%)0.12%$0 MNov 10, 2026
27Connective Capital Management, LLC293,624New0.12%$0 MNov 16, 2026
28BFC Planning, Inc.270,1700 (0.00%)0.11%$0 MNov 13, 2026
29Bridgeway Capital Management, LLC217,326-3,674 (-1.66%)0.09%$0 MNov 16, 2026
30Empowered Funds, LLC217,326New0.09%$0 MNov 13, 2026
31McMillan Office, Inc.216,0000 (0.00%)0.09%$0 MNov 13, 2026
32FMR LLC204,627+11,701 (+6.07%)0.08%$0 MNov 10, 2026
33Marshall Wace, LLP203,391-1,078,956 (-84.14%)0.08%$0 MNov 13, 2026
34Bank Of America Corp /de/200,303-224,070 (-52.80%)0.08%$0 MNov 16, 2026
35XTX Topco Ltd197,683+139,318 (+238.70%)0.08%$0 MNov 16, 2026
36LPL Financial LLC191,122+164,484 (+617.48%)0.08%$0 MNov 6, 2026
37Raymond James Financial Inc171,738+23,446 (+15.81%)0.07%$0 MNov 12, 2026
38Stifel Financial Corp162,308New0.06%$0 MNov 12, 2026
39Deutsche Bank AG\160,783-22,541 (-12.30%)0.06%$0 MNov 6, 2026
40Price T Rowe Associates Inc /MD/151,2330 (0.00%)0.06%$0 MNov 16, 2026
41Two Sigma Investments, LP127,573+72,626 (+132.17%)0.05%$0 MNov 16, 2026
42Rhumbline Advisers125,486-4,050 (-3.13%)0.05%$0 MNov 10, 2026
43Susquehanna International Group, LLP108,582+46,155 (+73.93%)0.04%$0 MNov 16, 2026
44HighTower Advisors, LLC104,870+5,000 (+5.01%)0.04%$0 MNov 10, 2026
45Jpmorgan Chase & Co104,545+18,019 (+20.82%)0.04%$0 MNov 12, 2026
46Williams Jones Wealth Management, LLC.101,3000 (0.00%)0.04%$0 MNov 5, 2026
47Invesco Ltd.99,001-1,128 (-1.13%)0.04%$0 MNov 12, 2026
48MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.89,387+4,530 (+5.34%)0.04%$0 MNov 16, 2026
49Vanguard Global Advisers, LLC86,682+887 (+1.03%)0.03%$0 MNov 13, 2026
50Connecticut Wealth Management, LLC86,249New0.03%$0 MOct 13, 2026
51Wealthspire Advisors, LLC80,0880 (0.00%)0.03%$0 MNov 13, 2026
52MetLife Investment Management, LLC79,604-30,697 (-27.83%)0.03%$0 MNov 16, 2026
53Wells Fargo & Company/mn71,006-112,111 (-61.22%)0.03%$0 MNov 16, 2026
54Police & Firemen's Retirement System of New Jersey54,3510 (0.00%)0.02%$0 MNov 9, 2026
55BNP Paribas Financial Markets49,976+12,073 (+31.85%)0.02%$0 MNov 12, 2026
56CIBC World Market Inc.46,890-160 (-0.34%)0.02%$0 MNov 10, 2026
57New York State Common Retirement Fund44,9000 (0.00%)0.02%$0 MNov 17, 2026
58Zacks Investment Management41,950-134 (-0.32%)0.02%$0 MNov 16, 2026
59Larson Financial Group LLC40,933+40,783 (+27188.67%)0.02%$0 MNov 5, 2026
60Voya Investment Management LLC37,2320 (0.00%)0.01%$0 MNov 10, 2026
61Rathbones Group PLC35,0000 (0.00%)0.01%$0 MNov 12, 2026
62Alliancebernstein L.P.34,0200 (0.00%)0.01%$0 MNov 16, 2026
63Equitable Holdings, Inc.30,0120 (0.00%)0.01%$0 MNov 16, 2026
64Prudential Financial Inc29,7950 (0.00%)0.01%$0 MNov 16, 2026
65StoneX Group Inc.29,747+12,739 (+74.90%)0.01%$0 MNov 3, 2026
66Tableaux LLC29,300New0.01%$0 MOct 23, 2026
67Point72 Asset Management, L.P.29,128New0.01%$0 MNov 16, 2026
68Kestra Advisory Services, LLC27,847-10,000 (-26.42%)0.01%$0 MNov 2, 2026
69Ascentis Independent Advisors25,245New0.01%$0 MNov 3, 2026
70Beirne Wealth Consulting Services, LLC25,000-20,000 (-44.44%)0.01%$0 MOct 19, 2026
71ProShare Advisors LLC23,138-991 (-4.11%)0.01%$0 MOct 29, 2026
72Principal Financial Group Inc22,500+8,397 (+59.54%)0.01%$0 MNov 2, 2026
73Royal Bank Of Canada22,376+16,385 (+273.49%)0.01%$0 MNov 16, 2026
74CIBC Bancorp USA Inc.22,018+11,844 (+116.41%)0.01%$0 MNov 13, 2026
75PFG Investments, LLC22,0020 (0.00%)0.01%$0 MNov 12, 2026
76Victory Capital Management Inc21,736+68 (+0.31%)0.01%$0 MNov 10, 2026
77Chapin Davis, Inc.20,000-29 (-0.14%)0.01%$0 MOct 9, 2026
78Allegheny Financial Group20,0000 (0.00%)0.01%$0 MNov 5, 2026
79Jane Street Group, LLC18,928-30,855 (-61.98%)0.01%$0 MNov 12, 2026
80Legal & General Group Plc17,9880 (0.00%)0.01%$0 MNov 16, 2026
81Axxcess Wealth Management, LLC17,790New0.01%$0 MOct 21, 2026
82Brevan Howard Capital Management LP17,466New0.01%$0 MNov 16, 2026
83Citigroup Inc17,433-69,170 (-79.87%)0.01%$0 MNov 4, 2026
84Xponance LLC17,219-303 (-1.73%)0.01%$0 MNov 3, 2026
85Ameritas Investment Partners, Inc.16,7240 (0.00%)0.01%$0 MNov 13, 2026
86Two Sigma Securities, LLC16,107-21,686 (-57.38%)0.01%$0 MNov 16, 2026
87Founders Capital Management16,0000 (0.00%)0.01%$0 MOct 13, 2026
88Private Advisor Group, LLC15,514New0.01%$0 MNov 10, 2026
89First Trust Advisors LP15,346New0.01%$0 MNov 12, 2026
90Anchyra Partners LLC15,141New0.01%$0 MOct 13, 2026
91Russell Investments Group, Ltd.15,136+399 (+2.71%)0.01%$0 MNov 6, 2026
92Mesirow Financial Investment Management, Inc.15,000-15,000 (-50.00%)0.01%$0 MNov 5, 2026
93Elgethun Capital Management15,0000 (0.00%)0.01%$0 MNov 13, 2026
94ELCO Management Co., LLC15,0000 (0.00%)0.01%$0 MOct 14, 2026
95SkyOak Wealth, LLC15,0000 (0.00%)0.01%$0 MOct 28, 2026
96MAI Capital Management14,3940 (0.00%)0.01%$0 MNov 12, 2026
97Creative Planning13,770+170 (+1.25%)0.01%$0 MNov 2, 2026
98Abel Hall, LLC13,090New0.01%$0 MOct 19, 2026
99Manufacturers Life Insurance Company, The12,829New0.01%$0 MNov 13, 2026
100Piscataqua Savings Bank12,4990 (0.00%)0.00%$0 MOct 21, 2026

All 143 institutional investors, with who bought and sold →

Mutual funds holding Lineage Cell Therapeutics, Inc.#

54 funds hold shares worth $31 M (about 9.5% of the company). Since their previous reports 45 added shares and 3 sold, buying $14 M net.
Mutual funds holding Lineage Cell Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.5.91 M$8 M2.3%<0.01%+6.4%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors4.16 M$5 M1.6%<0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.2.96 M$4 M1.2%<0.01%+15%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors1.73 M$2 M0.68%0.01%newJun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC1.99 M$2 M0.79%<0.01%newJul 31, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors1.32 M$2 M0.52%0.02%−18%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC1.20 M$2 M0.47%<0.01%−0.5%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors617,154$1 M0.24%0.05%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC438,359$1 M0.17%<0.01%no changeMay 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.447,526$0 M0.18%<0.01%newJul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC346,304$0 M0.14%<0.01%+5.3%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC344,484$0 M0.14%<0.01%newJun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC221,000$0 M0.09%0.20%no changeJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC245,384$0 M0.10%<0.01%newJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC193,554$0 M0.08%<0.01%newJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC171,911$0 M0.07%0.01%newJun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation136,900$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.107,870$0 M0.04%<0.01%+35%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.129,818$0 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC128,741$0 M0.05%<0.01%+8.4%Jul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.95,428$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.93,589$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.92,474$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC94,219$0 M0.04%<0.01%+18%Jul 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC88,027$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC62,541$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC51,620$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC51,282$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC41,359$0 M0.02%0.02%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS39,924$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC39,527$0 M0.02%0.01%+14%Jul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.30,400$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.28,908$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.27,784$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC27,439$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC32,042$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC24,358$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC22,374$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.21,668$0 M<0.01%<0.01%−20%Jul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC21,580$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC16,722$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management16,724$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC16,642$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC14,858$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC14,737$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS15,991$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC14,103$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC11,340$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC11,340$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC6,357$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC5,660$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.4,652$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC4,391$0 M<0.01%<0.01%+6.2%Jun 30, 2026
🇺🇸 LVIP Dimensional U.S. Core Equity 2 FundLincoln Financial Investments Corporation4,300$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 54 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Lineage Cell Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$99 K
4 purchases, 3 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$99 K
open market only
Insiders on file
39
since
$7.1 M$0Dec 2023: bought $11 K (1 trades), sold $0 (0 trades)Dec 23Feb 2024: bought $7.1 M (3 trades), sold $0 (0 trades)FebMay 2024: bought $11 K (1 trades), sold $0 (0 trades)MayAug 2024: bought $9 K (1 trades), sold $0 (0 trades)AugNov 2024: bought $65 K (4 trades), sold $0 (0 trades)NovJan 2025: bought $6.0 M (2 trades), sold $0 (0 trades)Jan 25Mar 2026: bought $24 K (1 trades), sold $0 (0 trades)MarNov 2026: bought $74 K (3 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Lineage Cell Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Brian M. CulleyPresident and CEO, DirectorBuy+40,500$0.916$37 K296,016Form 4
filed Deborah J. AndrewsDirectorBuy+25,000$0.800$20 K40,578Form 4
filed Jill Ann HoweChief Financial OfficerBuy+20,000$0.855$17 K45,500Form 4
filed Brian M. CulleyPresident and CEO, DirectorBuy+15,000$1.630$24 K255,516Form 4
filed Brian M. CulleyPresident and CEO, DirectorOption exercise+31,250——253,385Form 4
filed George A. Samuel IIIGeneral Counsel and SecretaryOption exercise+6,075——33,565Form 4
filed George A. Samuel IIIGeneral Counsel and SecretaryShares withheld for tax-2,502$1.800$5 K31,063Form 4
filed Brian M. CulleyPresident and CEO, DirectorShares withheld for tax-12,869$1.800$23 K240,516Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Lineage Cell Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
24.3 M
10.0% of shares · 19.27 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 4,298 shares at $1.03
  • : 24,893 shares at $0.99
  • : 26,826 shares at $0.91
  • : 9,441 shares at $1.03
  • : 5,939 shares at $0.90

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Lineage Cell Therapeutics, Inc. scorecard#

Passes 3 of the 20 checks that could be worked out: strongest in growth (2 of 6), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' median148.9×P/E 148.9× against Biotechnology's median of 17.5×.
    • ✗Price to book below its peers' median5.8×Price to book 5.8× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median24.0×Price to sales 24.0× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-7.5%Free cash flow is -7.5% of the market value.
    • ✗Earnings yield above the 10-year Treasury yield0.7%Earnings yield 0.7% against the 10-year Treasury's 5.15% on 2026-11-13.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth2 of 6
    • ✓Revenue grew in the newest year53.3%Revenue up 53.3% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-0.3%-0.3% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-0.3%-0.3% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-0.28 vs -0.09Diluted EPS -0.28 in fiscal 2025 against -0.09 the year before (report's currency).
    • ✗Net income higher than five years earlier-$64 M-$64 M in fiscal 2025 against -$21 M in 2020.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
  • Profitability0 of 5
    • ✗Profitable in the newest year-$64 MNet income -$64 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-251.5%-251.5% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-103.4%-103.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-251.5%-251.5% in fiscal 2025 against -153.2% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities5.2×Current ratio 5.20 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-3.98Z-score -3.98 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year14.9%Diluted shares up 14.9% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Lineage Cell Therapeutics, Inc.'s statements, beside the median of Biotechnology.

Lineage Cell Therapeutics, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-251.5%-60.5%
Net margin-436.3%-68.9%
Return on equity-103.4%-61.0%
Revenue growth, 3 years a year-0.3%12.9%
Revenue growth53.3%15.8%
Free cash flow margin-133.5%-61.5%

3of 7on the Piotroski tests of financial strength

  • Net loss of $64 million, the 9th loss-making year in a row.
  • Free cash flow was negative: -$19 million.
  • The share count rose 14.9% in the year.

Lineage Cell Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Lineage Cell Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue159.58.9154.31.83.55.03.55.9
Cost of revenue—0.30.70.71.40.40.40.30.20.4
Gross profit——8.3142.91.43.14.73.35.6
Research and development18121614341218212436
General and administrative18181723181624252028
Operating expenses——3336522842464465
Total costs and expenses513134———————
Operating income−37−21−25−23−49−26−39−42−39−59
Net interest income———0.80.01.0————
Share of profit of associates—————————−4.7
Other non-operating income (expense)−322.91.5−3.35.94.520−5.31678
Income before tax−69−19−23−26−43−22−19−47−2319
Income tax−5.30−1.80.5—−1.2−7.4r0.3r——
Net income including minority interests−63−19−21−26−43−21−12−47−2319
Minority interests' share of net income0.20.00.0−0.1−0.3−0.0−0.1−0.8−3.3−15
Net income attributable to shareholders−64−19−21−26−43−21−12−46−2034
Earnings per share, basic-0.28-0.09-0.12-0.15-0.26-0.14-0.08-0.36-0.170.35
Earnings per share, diluted-0.28-0.09-0.12-0.15-0.26-0.14-0.08-0.36-0.170.34
Shares, weighted average (basic)230200173170165———11497
Shares, weighted average (diluted)2302001731700.20.20.10.1r114100
Balance sheet
Cash and cash equivalents4146351156339.5243722r
Short-term investments152.00.1472.69.0217.21.3—
Receivables0.90.60.70.351—0.00.10.10.3
Other current assets2.52.62.21.82.42.42.91.9r1.41.8
Current assets595138601124458364326
Property, plant and equipment2.62.32.2r5.74.95.68.25.85.55.5
Right-of-use (leased) assets2.12.12.5——0.20.8———
Goodwill11111111111111———
Other intangible assets324747474747483.16.910
Investments in associates—————————0
Total assets113113101124175108125102173143
Accounts payable2.31.22.12.43.52.62.42.40.91.6
Current liabilities11141819477.86.56.86.98.9
Lease liabilities (non-current)1.51.32.02.91.92.53.91.9——
Total liabilities693639528413149.49.012
Retained earnings−467−403−385−363−337−294−273−262−216−196
Shareholders' equity45786373929611392r163118
Minority interests−1.2−1.4−1.4−1.4−1.3−1.1−1.7−1.61.613
Total equity43776272919511192164131
Total liabilities and equity113113101124175108125102173143
Shares outstanding243220175170169153150r127127103r
Cash-flow statement
Depreciation and amortization0.70.60.60.60.70.81.01.10.91.2
Share-based compensation4.85.14.64.33.52.23.65.43.98.0
Cash from operating activities−19−23−291.1−24−20−32−31−31−42
Capital expenditure−0.5−0.6−0.7−0.4−0.3r−0.1−0.4−0.6−1.3−2.2
Cash from investing activities−13−2.346−469.7131712−10−11
Debt repaid——————−0.1−0.1−0.0—
Shares issued——6.60.1315.10.1—4920
Cash from financing activities27366.41.637300.65.85533
Exchange-rate effect on cash0.4−0.1−0.3−0.9———0.00.10.3
Change in cash−5.01024−442323−14−1315−20
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Lineage Cell Therapeutics, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Collaboration Revenues$14 M93%
  • Event Based Milestones and Other Collaborative Revenue$7 M49%
  • Upfront license fees$6 M44%
  • Royalties, License and Other Revenues$1 M6.5%

Countries and regions

  • Non-US(total)$3 M17%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Lineage Cell Therapeutics, Inc. operates: 3 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.

Lineage Cell Therapeutics, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office—
🇮🇱 Israel1 subsidiary—
🇸🇬 Singapore1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Lineage Cell Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.1 M
Brian Culley
Other top executives, average
$992 K
the CEO earned 2.1× this
$100 invested is now
$95
Lineage Cell Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Brian Culley$2.1 M$6.3 M$992 K$95
2024Brian Culley$2.5 M$707 K$1.1 M$28
2023Brian Culley$2.9 M$2.2 M$937 K$62

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Lineage Cell Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling
  • Auditor changedFiling

Auditor changed 2 · Acquisition or sale completed 1 · Directors and officers 1 · Material agreement 2 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 11

Lineage Cell Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Acquisition or sale completedMaterial agreementUnregistered share saleResults announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Auditor changed8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Auditor changed8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Lineage Cell Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2014$4 MPrivate placement after listing$2 to $10 million3equity, optionsSEC
Mar 2011$4 MIssued in a merger or acquisition$2 to $10 million20equity, optionsSEC
Jan 2011$2 MIssued in a merger or acquisition$2 to $10 million8equitySEC
May 2010$8 MNo. 3$2 to $10 million2equitySEC
May 2009$8 MNo. 2$2 to $10 million2equity, optionsSEC
Apr 2009$4 MNo. 1$2 to $10 million29equity, debtSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Lineage Cell Therapeutics, Inc. compares in Biotechnology

  • Market cap$261 M · higher than 49% of 726
  • Revenue$15 M · higher than 47% of 647
  • Net margin16.1% · higher than 82% of 408
  • Revenue growth53.3% · higher than 73% of 438
  • P/E ratio148.9× · lower than 6% of 100
  • Price / sales24.0× · lower than 28% of 339
  • Price / book5.8× · lower than 27% of 534
  • FCF yield-7.5% · higher than 63% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Lineage Cell Therapeutics, Inc.🇺🇸$261 M148.9×16.1%+53.3%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, Wikidata, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Lineage Cell Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Lineage Cell Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Lineage Cell Therapeutics, Inc.? Suggest a correction